Phase 2
Completed N=20
Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy
Source: ClinicalTrials.gov NCT01150461 ↗Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Sep 2013
Primary outcomePrimary: Percentage Change From Baseline in Extent of Left Ventricular Fibrosis at 1 Year as Assessed by Magnetic Resonance Imaging. — -23; 31 Percentage change in fibrotic myocardium — p=0.02
Summary
The purpose of this study is to determine whether taking losartan helps people with hypertrophic nonobstructive cardiomyopathy feel better by decreasing the amount of heart muscle thickening and/or the amount of heart muscle scarring.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage Change From Baseline in Extent of Left Ventricular Fibrosis at 1 Year as Assessed by Magnetic Resonance Imaging. |
-23; 31 | 0.02 sig |
| SECONDARY Percentage Change From Baseline in Left Ventricular Mass at 1 Year as Assessed by Magnetic Resonance Imaging. |
-5; 5 | 0.06 |
Eligibility Criteria
Inclusion Criteria
- Patients with hypertrophic cardiomyopathy
- Left ventricular outflow tract (LVOT) gradient less than 30 mm Hg at rest
- Age 18 years or older
Exclusion Criteria
- Contraindication to losartan
- Already taking losartan
- Contraindication to MRI
- Hemodynamic instability
Data sourced from ClinicalTrials.gov (NCT01150461). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.